Mita, K.; Izumi, K.; Goriki, A.; Tasaka, R.; Hatayama, T.; Shima, T.; Kato, Y.; Kamiyama, M.; Inoue, S.; Tanaka, N.;
et al. Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa. Cancers 2024, 16, 508.
https://doi.org/10.3390/cancers16030508
AMA Style
Mita K, Izumi K, Goriki A, Tasaka R, Hatayama T, Shima T, Kato Y, Kamiyama M, Inoue S, Tanaka N,
et al. Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa. Cancers. 2024; 16(3):508.
https://doi.org/10.3390/cancers16030508
Chicago/Turabian Style
Mita, Koji, Kouji Izumi, Akihiro Goriki, Ryo Tasaka, Tomoya Hatayama, Takashi Shima, Yuki Kato, Manabu Kamiyama, Shogo Inoue, Nobumichi Tanaka,
and et al. 2024. "Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa" Cancers 16, no. 3: 508.
https://doi.org/10.3390/cancers16030508
APA Style
Mita, K., Izumi, K., Goriki, A., Tasaka, R., Hatayama, T., Shima, T., Kato, Y., Kamiyama, M., Inoue, S., Tanaka, N., Hoshi, S., Okamura, T., Yoshio, Y., Enokida, H., Chikazawa, I., Kawai, N., Hashimoto, K., Fukagai, T., Shigehara, K.,
... Mizokami, A.
(2024). Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa. Cancers, 16(3), 508.
https://doi.org/10.3390/cancers16030508
